About: http://data.cimple.eu/news-article/85a3e8895fcfea9b3143bef6a817bdeffa563023568cf280840ff2a5

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/85a3e8895fcfea9b3143bef6a817bdeffa563023568cf280840ff2a5 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The EU is to sign a contract with German pharmaceutical company CureVac for another potential Covid-19 vaccine, European Commission chief Ursula von der Leyen said Monday. The deal, to be signed Tuesday, brings to five the number of vaccines the EU will have in its portfolio, with a sixth, from US firm Moderna, on its way, von der Leyen said in a video statement. The portfolio already includes a contract for 300 million doses of a vaccine produced by German company BioNTech and US giant Pfizer which both manufacturers say has proven 90 percent effective against Covid-19. "The coronavirus continues to spread rapidly across Europe. We need a safe and effective vaccine to end this pandemic", von der Leyen said. The CureVac contract is an option to buy up to 405 million doses if its vaccine is proven to be safe and effective. Von der Leyen did not disclose the financial terms, in line with the same confidentiality given the other companies making candidate vaccines. The EU chief said the European Medicines Agency would assess the potential vaccines and only authorise them if they passed health standards. "This is why we need to have a broad portfolio of vaccines based on very different technologies," von der Leyen said. The European Union's population is 450 million. It is unknown at this stage how long the effects of a viable vaccine might last or if one, two or more jabs could be needed to create human resistance to the coronavirus. No vaccine has yet been shown to be effective for large-scale production, but there are hopes at least one might be rushed to market by early next year. Clinical results from the BioNTech-Pfizer vaccine are still being evaluated. Both Russia and China declare they have each produced working vaccines, but have not given complete clinical information so that Western regulatory agencies might weigh them for public use. Aware of criticism that wealthy countries were snapping up millions of doses of possible vaccines, von der Leyen stressed that the EU was working with a World Health Organization-backed initiative called COVAX to get successful Covid-19 jabs to poorer nations. rmb/dc/wai
schema:headline	EU expands vaccine options with CureVac contract
schema:mentions	Confidentiality European Commission Renminbi House of Leyen European Medicines Agency USA Gymnastics Pharmaceutical industry Ursula von der Leyen European Union Russia Pandemic Pfizer Vaccine United States China Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 The Portfolio CureVac Von der Leyen Commission Mark Roebuck
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-11-16 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	76 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software